The effect of synbiotics during neoadjuvant chemo(radio)therapy for esophageal cancer in preventing bacterial translocation and postoperative infectious complications

The effect of synbiotics during neoadjuvant chemo(radio)therapy for esophageal cancer in preventing bacterial translocation and postoperative infectious complications - The effect of synbiotics during neoadjuvant chemo(radio)therapy for esophageal cancer in preventing bacterial translocation and postoperative infectious complications

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000007651

Enrollment

Registered

2012-04-03

Start date

2012-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophageal cancer

Interventions

Synbiotic treatment during chemo(radio)therapy

oral intake, Yakult 400 (Yakult Honsha, Tokyo, Japan) containing living Lacobacillus casei strain Shirota

BifieneS (Yakulut Honsha) containing living Bifisobacterium breve strain Yakult and galactooligosaccharides. Postoperative symbiotic treatment, through the enteral feeding tube, Yakult BL Seichoyaku

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with resctable esophageal cancer requiring neoadjuvant chemo(radio)therapy

Exclusion criteria

Exclusion criteria: Patients with infectious disease before chemo(radio)therapy Patients with previous chemo(radio)thrapy

Design outcomes

Primary

Measure	Time frame
Existance of bacterical translocation	—

Secondary

Measure	Time frame
Side effect of chemo(radio)therapy Inflammatory marker during chemo(radio)therapy Statement of nurtrition after chemo(radio)therapy Permeability of intestinal mucosa Grading of atrophy of intestinal mucosa Postoperative complication Inflammatory marker after surgery	—

Countries

Japan

Contacts

Public ContactMasahide Fukaya

Nagoya University Graduate School of Medicine Division of Surgical Oncology, Department of Surgery

mafukaya@med.nagoya-u.ac.jp052-744-2222

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026